TY  - CONF

T1  - Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial

JO  - BRITISH JOURNAL OF HAEMATOLOGY

PY  - 2016/04/01

AU  - Ashcroft AJ

AU  - Cairns DA

AU  - Williams C

AU  - Hockaday A

AU  - Cavanagh JD

AU  - Snowden JA

AU  - Parrish C

AU  - Yong K

AU  - Cavet J

AU  - Hunter H

AU  - Bird JH et al

ED  - 

VL  - 173

SP  - 165

EP  - 165

Y2  - 2024/12/22

ER  -